PubMed Health⌕ Search

Biomedical subjects

R A Staub

Publications and source records attributed to R A Staub.

7 recordsLinked to original sources

Plasma and cerebrospinal fluid concentration of phenylacetic acid in humans and monkeys.

A rapid and reliable mass-fragmentographic method for assay of plasma and cerebrospinal fluid (CSF) concentrations of free and conjugated phenylacetic acid (PAA) is described. The method is used to compare plasma and CSF concentrations of PAA in humans and monkeys. Both packed and capillary columns are used. In humans approximately 45% of total plasma PAA is conjugated in contrast to approximately 60% in monkeys. Both free and conjugated PAA concentrations tend to be higher in monkeys than in humans. Plasma mean concentration of total PAA in humans and monkeys are, respectively, 459.1 and 838 ng/ml. Approximately 55 and 25% of total PAA in the CSF are conjugated in humans and monkeys, respectively. Total PAA mean concentrations in human and monkey CSF are 41.6 and 84.2 ng/ml. Because over 90% of total urine PAA in humans is conjugated, it is concluded that over 50% of urine phenylacetylglutamine may be derived from kidney conjugation of free plasma PAA and/or from the kidney's preferential filtration of conjugated PAA as contrasted with free PAA.

Animals↗

Lymphocyte monoamine oxidase and plasma prolactin and growth hormone in tardive dyskinesia.

Twelve elderly women with tardive dyskinesia were matched with 12 patients without dyskinesia. Lymphocyte monoamine oxidase (MAO) activity and plasma prolactin and growth hormone concentrations were determined "blind" in these 12 pairs of patients. Chronic schizophrenic patients with tardive dyskinesia had significantly lower lymphocyte MAO activity as compared to controls. Organic brain syndrome patients with dyskinesia did not differ from controls in the lymphocyte MAO activity. These results with lymphocyte MAO parallel our earlier findings on platelet MAO. No significant differences were found between dyskinesia group and controls in the plasma prolactin and growth hormone concentrations. Possible implications of our findings are discussed.

Aged↗

Drug effect on blink rates in rhesus monkeys: preliminary studies.

Various drugs that alter central monoamine activity were given to monkeys to determine effects on blink rate. Chronic pargyline treatment raised the mean +/- SD blink rate slightly to 18.2 +/- 5.3 blinks/90 sec. When phenylethylamine was added to chronic pargyline treatment, blinks increased from a base line of 16.8 +/- 7.6 blinks/90 sec to 37 +/- 15 blinks/90 sec. Apomorphine (0.36 mg/kg) raised blinks from a base lone of 12.2 +/- 2.8 blinks/90 sec. to 41.9 +/- 10.3 blinks/90 sec. and reversed a decrease in blinking caused by haloperidol. The neurochemical basis of blinking and implications for tardive dyskinesia are discussed.

Animals↗

Lymphocyte monoamine oxidase activity and chronic schizophrenia.

Lymphocyte monoamine oxidase (MAO) activity was assayed in 62 chronic schizophrenic patients, 113 normal volunteers, and 23 first-degree relatives of schizophrenic patients. Mean lymphocyte MAO activity was significantly lower (p < 0.001) in the chronic schizophrenic group than in controls; first-degree relatives had a mean lymphocyte MAO activity midway between the schizophrenics and normals. No relationship was found between lymphocyte MAO activity and sex or age of subjects. When subjects were subgrouped by race, blacks had significantly lower MAO activity than whites (p < 0.001).

Adolescent↗

Monoamine oxidase inhibitors potentiate phenylethylamine effects in rhesus monkeys.

Acute pretreatment with either a Type A monoamine oxidase inhibitor (MAOI), clorgyline, or a Type B MAOI, pargyline, markedly reduced the dose of phenylethylamine (PEA) required to produce checking and a variety of other behavioral changes in rhesus monkeys. Doses of PEA (5 or 10 mg/kg) which previously were without effect, now produced significant behavioral changes in pretreatment animals.

Animals↗